Mes: febrero 2021

Toyota and Philabundance Help Alleviate Childhood Hunger in Philadelphia

PHILADELPHIA, Feb. 2, 2021 /PRNewswire/ — Prior to the COVID-19 pandemic, one in five people in Philadelphia were food-insecure. This number, which was already higher than the national average, has been heightened throughout the past year – and local children are among the most critical in-need, missing vital access to free food programs through school due to the pandemic’s impact. Philadelphia’s child food insecurity rate in 2020 is…

PHILADELPHIA, Feb. 2, 2021 /PRNewswire/ — Prior to the COVID-19 pandemic, one in five people in Philadelphia were food-insecure. This number, which was already higher than the national average, has been heightened throughout the past year – and local children are among the most critical in-need, missing vital access to free food programs through school due to the pandemic’s impact. Philadelphia’s child food insecurity rate in 2020 is projected at over 32 percent, and the need to support the local childhood community has never been more important.

Philabundance (a hunger relief organization serving Greater Philadelphia and a member of Feeding America) is at the forefront of the fight against childhood food insecurity and needs assistance from the community, now more than ever. «For food banks across the country, much of the past year has been focused on adapting to meet the 60 percent increase in need that we’ve seen because of COVID,» explained Philabundance CEO Loree Jones. «With children remote learning due to the pandemic, many don’t have access to the school meals they depended on to get through the day. This made our BackPack Program aimed at feeding children more important than ever.»

Philabundance’s BackPack Program delivers much-needed free food for kids, providing three to five pounds of shelf-stable food (equating to 24 meals), per backpack. Altogether, this monthly food distribution provides over 30,000 kids and their families with access to nutritious food each month. And, every one of the more than 7,000 BackPacks Philabundance distributes each month also provides suggested recipes to further assist these families.

Prior to COVID-19, Philabundance’s BackPack Program was facilitated through local schools, with children looking forward to the array of food and snacks they received monthly. Due to COVID-19 and shifting to remote learning, Philabundance pivoted the program to serve students through its agency network of food pantries, community centers and more. The 24 sites that will distribute the BackPacks are located in zip codes with some of the highest rates of food insecurity in Greater Philadelphia.

To help Philabundance provide Philadelphia children and their families with these nutritious meals, Toyota, its local Toyota Dealers and many business partners across Greater Philadelphia have come together under a new donation drive and media campaign, branded Lil’ Abundance, that will both raise awareness for children’s food insecurity and fund two-months-worth of free food to kids and their families through Philabundance’s BackPack Program.

«Every year, Toyota and the Dealers are deeply humbled by the chance to join with our local business partners to help Philabundance fight hunger here in the Delaware Valley. There are a lot of things people should be, and ‘hungry’ is just not one of them,» said Paul Muller, president of the Tri-State Toyota Dealers Association (comprised of 25 dealerships in Pennsylvania, New Jersey and Delaware). «This year, especially, the need was clear to help Philabundance with their programs to support local children and their families facing hunger during unconscionable – and in many ways, unprecedented – challenges. Toyota and about two dozen of our local business partners came together to create and launch the first-ever Lil’ Abundance campaign to ‘help feed lil’ mouths.'»

Through the Lil’ Abundance campaign, Toyota, the Tri-State Toyota Dealers and local business partners have come together to enable Philabundance with the ability to provide meals to children and their families – all distributed safely and socially-distanced, given the current circumstances stemming from COVID-19. In total, Toyota and its partners’ Lil’ Abundance campaign efforts will provide Philabundance with two full months of BackPack Program funding, providing free food for kids and more than 345,000 meals.

«Toyota and our local Dealers have always made it our mission to give back to the community,» said Ben Pyle, general manager of Toyota’s Central Atlantic Region, which includes Pennsylvania and Delaware. «Working with Philabundance again this year gives us the chance to support local families in an incredibly impactful way during such a challenging time. We’re happy to support this important cause and bring relief to our neighbors in need.»

Similar to the annual «Toyota Tundra Food Drives,» the Tri-State Toyota Dealers Association, along with both Toyota Motor North America and Toyota Financial Services, joined forces with more than 20 of the Dealers’ local business partners (including television/cable outlets, radio stations, local print and outdoor companies, and Philadelphia’s professional sports organizations) to collectively create and contribute to the Lil’ Abundance campaign in support of the important ongoing food distributions Philabundance’s BackPack Program provides to children and their families.

«As the local Toyota Dealers living and working in our communities, we’ve been blown away by the support from our media and professional sports partners to come together and help our friends at Philabundance truly make a difference in people’s lives,» said Paul Muller. «The past year has served as a stark reminder of the food insecurity within our communities, and it’s more important than ever that we work together to put an end to childhood hunger in Philadelphia and continue to find meaningful opportunities to give back to those who need it most right now.»

«We’re extremely proud of the effort and the incredible impact Lil’ Abundance will have. We are grateful for our longstanding partnership with Philabundance, which year after year has given Toyota and our Dealers such meaningful opportunities to make a positive difference within local communities,» added Briana Nelson, general manager of Toyota’s New York Region, which includes southern New Jersey. «It’s been an honor to come together again this year on Lil’ Abundance to fight hunger and provide healthy and nutritious meals to children and families in-need across our region, especially now when this support needed more than ever.»

The Lil’ Abundance campaign efforts have enabled Philabundance’s BackPack Program efforts in January-February 2021. However, there remains another 10 months of the calendar year when Philabundance needs support from businesses and individuals across Greater Philadelphia’s communities to help food insecure children and their families.

«Instead of just canceling the annual Haul Away Hunger event, Toyota and their partners pivoted with us to help serve one of our most vulnerable populations: children. No child should have to wonder where their next meal is coming from, and thanks to Toyota and its partners, thousands of kids across Philadelphia won’t have to,» added Loree Jones. «We hope other individuals and organizations can be inspired to help us on our mission to end childhood hunger, for good.»

To find out how you can help aid hunger relief through Lil’ Abundance and beyond, text DONATEFOOD to 44321 or visit www.philabundance.org. Join the conversation on social media with the hashtags #beethunger and #ToyotaLilAbundance, and tag @toyotausa and @philabundance on Instagram. For those seeking food assistance immediately, please call 1-800-5-HUNGRY or visit Philabundance’s website: www.philabundance.org/find-food.

Media Contacts
Micholl Azenon
347-271-2869
Micholl.Azenon@toyota.com

Emily Whelahan
914-255-0969
Emily.Whelahan@allisonpr.com

About Philabundance

Philabundance is driving hunger from our communities today and working to end hunger for good. It distributes more than 50 million pounds annually through a network of 350 partners including food pantries, houses of worship, hospitals, schools, libraries and other service providers. Philabundance serves 135,000 people each week including children, seniors, college students, single parents and people who are working– a number that continues to grow due to the impact of the COVID-19 pandemic. Give now or learn more at Philabundance.org.

About Tri-State Toyota Dealers Association

The Tri-State Toyota Dealers Association (TDA) is comprised of 25 Toyota Dealers in the Greater Philadelphia market dedicated to providing customers in Southeastern Pennsylvania, Northwestern Delaware and Southern New Jersey communities with Toyota sales and service. The Tri-State TDA has an ongoing partnership with multiple community organizations and causes, including the association’s focus on hunger relief in the Delaware and Lehigh Valleys through initiatives such as the annual «Toyota Tundra Food Drives» in Philadelphia and Allentown and supporting the «Phans Feeding Families» initiative with the Philadelphia Phillies.

About Toyota

Toyota (NYSE:TM) has been a part of the cultural fabric in North America for more than 60 years, and is committed to advancing sustainable, next-generation mobility through our Toyota and Lexus brands plus our 1,800 dealerships. 

Toyota has created a tremendous value chain and directly employs more than 47,000 in North America. The company has contributed world-class design, engineering, and assembly of more than 40 million cars and trucks at our 14 manufacturing plants, 15 including our joint venture in Alabama that begins production in 2021.

Through its Start Your Impossible campaign, Toyota highlights the way it partners with community, civic, academic and governmental organizations to address our society’s most pressing mobility challenges. We believe that when people are free to move, anything is possible. For more information about Toyota, visit www.toyotanewsroom.com.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/toyota-and-philabundance-help-alleviate-childhood-hunger-in-philadelphia-301219883.html

SOURCE Toyota

Maxim Integrated Unveils Industry’s First Data Acquisition System to Achieve ASIL-D Compliance for Voltage, Current, Temperature and Communication of a Battery Management System

SAN JOSE, Calif., Feb. 2, 2021 /PRNewswire/ — Designers of automotive battery management systems (BMS) can now deliver the highest level of safety for voltage, current, temperature and communication while also saving space and reducing solution cost, with the MAX17852 14-channel, high-voltage, ASIL-D data-acquisition system from Maxim Integrated Products, Inc. (NASDAQ: MXIM). Designed for integration within electric vehicles, hybrid electric vehicles and other transportation…

SAN JOSE, Calif., Feb. 2, 2021 /PRNewswire/ — Designers of automotive battery management systems (BMS) can now deliver the highest level of safety for voltage, current, temperature and communication while also saving space and reducing solution cost, with the MAX17852 14-channel, high-voltage, ASIL-D data-acquisition system from Maxim Integrated Products, Inc. (NASDAQ: MXIM). Designed for integration within electric vehicles, hybrid electric vehicles and other transportation systems, the IC is ideal for smart junction box, 48V and other automotive battery systems which can see voltages up to 400V and beyond.   

OEMs and electric vehicle manufacturers require that all battery systems meet the highest safety requirements set by the ISO26262 guidelines. Through comprehensive diagnostics and a safety-driven architecture, Maxim Integrated designed and manufactured the MAX17852 to enable customers to design their systems to meet the highest ASIL-D standards for voltage, current, temperature and communication. The small, cost effective IC also offers the highest accuracy for delivering voltage, current and temperature data with tight time synchronization. It allows a typical cell voltage measurement of ±0.45mV at room temperature and a maximum of ±2mV error in a temperature range of 5 degrees to 40 degrees Celsius, enabling car OEMs to get the most mileage range out of their batteries. With a current sense amplifier capability of +/-300mV, and a gain setting up to 256 times and 0.3 percent current sense gain error, the MAX17852 provides the fastest, most accurate data for calculating power management, state of health and state of charge. The 14-channel battery data acquisition system integrates a current sense amplifier so that current information is acquired at the same time as cell voltage and temperature. The MAX17852 allows both hall effect sensor and shunt resistors to be used as sensing components.

Key Advantages

  • Highest Safety: ASIL-D rating for voltage, current, temperature and communication enhances safety
  • Highest Accuracy: Measurement accuracy with best current sense amplifier gain error to allow accurate, time-aligned current measurements to potentially boost mileage
  • Smaller Size: High integration enables up to 16 percent smaller size than a discrete solution to save board space
  • Lower Cost: Integrated current sense amplifier provides up to 20 percent cost savings
  • Versatility: The first device that can be adapted to many applications with voltage, current and temperature sensing

Commentary

  • «Enabling systems to achieve the highest level of safety (ASIL D) for a BMS system is really a must for consumers to feel safe in their electrified vehicles,» said Tamer Kira, executive director for the Automotive Business Unit at Maxim Integrated. «The MAX17852 is the fastest and most accurate in voltage, current and temperature measurements and that is why it is the first battery data acquisition system in the industry to achieve the highest safety rating for all the major components of a BMS system.»

Availability and Pricing

  • The MAX17852 is available at Maxim’s website for $7.52 (1000-up, FOB USA); also available from authorized distributors
  • The MAX17852EVKIT# evaluation kit is available for $250

About Maxim Integrated
Maxim Integrated, an engineer’s engineering company, exists to solve the designer’s toughest problems in order to empower design innovation. Our broad portfolio of high-performance semiconductors, combined with world-class tools and support, delivers essential analog solutions including efficient power, precision measurement, reliable connectivity and robust protection along with intelligent processing. Designers in application areas such as automotive, communications, consumer, data center, healthcare, industrial and IoT trust Maxim to help them quickly develop smaller, smarter and more secure designs. Learn more at https://www.maximintegrated.com. 

Contact:    

Gayle Bullock

408-464-2516

Gayle.Bullock@maximintegrated.com

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/maxim-integrated-unveils-industrys-first-data-acquisition-system-to-achieve-asil-d-compliance-for-voltage-current-temperature-and-communication-of-a-battery-management-system-301219444.html

SOURCE Maxim Integrated Products Inc.

RedHill Biopharma anuncia valoración positiva de la futilidad del DSMB para el estudio de fase 2/3 de opaganib para la COVID-19

TEL AVIV, Israel y RALEIGH, Carolina del Norte, 2 de febrero de 2021 /PRNewswire/ — RedHill Biopharma Ltd. (Nasdaq: RDHL) («RedHill» o la «Compañía»), una compañía especializada en la biofarmacéutica, anunció hoy que el Comité de Monitoreo de Datos y Seguridad (DSMB) independiente designado para el estudio global en fase 2/3 de opaganib[1] en pacientes con COVID-19…

TEL AVIV, Israel y RALEIGH, Carolina del Norte, 2 de febrero de 2021 /PRNewswire/ — RedHill Biopharma Ltd. (Nasdaq: RDHL) («RedHill» o la «Compañía»), una compañía especializada en la biofarmacéutica, anunció hoy que el Comité de Monitoreo de Datos y Seguridad (DSMB) independiente designado para el estudio global en fase 2/3 de opaganib[1] en pacientes con COVID-19 grave recomendó de manera unánime la continuidad del estudio, después de una valoración preprogramada de futilidad de los datos no cegados para los primeros 135 pacientes tratados en el estudio, así como de la información de seguridad de los primeros 175 pacientes. 

 

RedHill Biopharma Logo

 

«Opaganib es un nuevo inhibidor de la esfingosina quinasa-2 (SK2) administrado por vía oral con una actividad antiviral, antiinflamatoria y antitrombótica demostrada. La recomendación positiva y unánime del DSMB es un hito importante en el progreso de nuestro programa de desarrollo para la enfermedad de COVID-19. Junto con los resultados positivos del estudio de fase 2, esta recomendación unánime del DSMB para continuar el estudio global de fase 2/3 sugiere que vamos en la dirección correcta desde una perspectiva de seguridad y eficacia», comentó Mark L. Levitt, M.D., Ph.D., director médico de RedHill. «Este es un momento particularmente difícil en la lucha contra la pandemia, con mutaciones virales que aumentan las tasas de infección e impactan muchos aspectos de la respuesta de la sociedad a la pandemia. La necesidad de terapias eficaces es clara. El mecanismo de acción de Opaganib de dirige al componente SK2 de la célula humana huésped, que está involucrado tanto en la replicación viral dentro de la célula como en las respuestas inflamatorias/inmunes posteriores. Esto significa que se espera que el opaganib mantenga su actividad independientemente de las preocupantes mutaciones en la proteína spike SARS-CoV-2. Estas mutaciones subrayan el potencial del SARS-CoV-2 para desarrollar resistencia a los mAbs antivirales directos y para afectar potencialmente la efectividad de la vacuna. Esta es una ventaja importante del opaganib ante la creciente multitud de cepas virales, y promete ser una opción de tratamiento muy necesaria que puede ayudar a que los pacientes sean desconectados del oxígeno suplementario y salgan pronto del hospital».

Esta valoración de futilidad positiva por parte del DSMB, que sugiere que el estudio global de fase 2/3 avanza como se esperaba, se suma a los datos positivos de seguridad y eficacia de primera línea del estudio de fase 2 en los Estados Unidos, en el que el opaganib demostró mejoría en la reducción del requerimiento de oxígeno al final del tratamiento, el día 14, en los resultados clave de eficacia primaria y secundaria, lo que se correlaciona con la mejoría clínica según la escala ordinal de la Organización Mundial de la Salud (OMS). Los datos de la fase 2 tampoco mostraron diferencias sustanciales de seguridad entre los brazos de tratamiento tratados con opaganib y placebo, lo que se suma a la creciente base de datos de seguridad para el opaganib. En las próximas semanas se espera un análisis completo de los datos de la fase 2, incluidos los análisis de biomarcadores virales e inflamatorios, los factores de riesgo basales y la estratificación del estándar de cuidado para el tratamiento de base, los cuales se compartirán con pares para su valoración.

En línea con la rápida evolución de la práctica clínica y las directrices para el tratamiento de pacientes hospitalizados con COVID-19, cuyo objetivo es minimizar la intubación y la ventilación mecánica de los pacientes, la variable principal del estudio global de fase 2/3 ahora es la proporción de pacientes que al día 14 logran respirar por sí solos (ya no requieren oxígeno suplementario), lo que anteriormente era una una variable clave secundaria. La intubación y la ventilación mecánica siguen siendo una variable secundaria. En consecuencia, se planea un ajuste ciego del estudio para aproximadamente 460 pacientes. En la actualidad se cuenta con aproximadamente 30 sedes para el estudio en 7 países, y durante los próximos días y semanas se agregarán más sedes y países. Para el segundo trimestre de 2021 se espera contar con datos de primera línea y aplicaciones para autorización de uso potencial en emergencias a nivel global.

Acerca de Opaganib (Yeliva®, ABC294640) 

El opaganib, una nueva entidad química patentada y primera en su categoría, es un novedoso inhibidor selectivo de la esfingosina quinasa-2 (SK2) que se administra por vía oral, con actividad dual antiviral e inflamatoria demostrada que apunta al componente celular en el huésped que se encarga de la replicación del virus, y puede reducir la probabilidad de desarrollar resistencia del virus. El opaganib también ha mostrado actividad anticancerígena y tiene el potencial de apuntar a múltiples indicaciones oncológicas, virales, inflamatorias y gastrointestinales.

El opaganib recibió la designación de medicamento huérfano de la Administración de Alimentos y Medicamentos (FDA) de los Estados Unidos para el tratamiento del colangiocarcinoma y se está evaluando en un estudio de fase 2a para pacientes con colangiocarcinoma avanzado y en un estudio de fase 2 para pacientes con cáncer de próstata. El opaganib también está siendo evaluado como tratamiento para la neumonía por COVID-19 en un estudio global de fase 2/3 y ha evidenciado señales positivas de seguridad y eficacia en los datos preliminares de primera línea de un estudio de fase 2 en los Estados Unidos.

Los datos preclínicos han demostrado las actividades antiinflamatorias, antivirales y antitrombóticas del opaganib, con el potencial de aliviar trastornos inflamatorios del pulmón, como la neumonía, y de mitigar el daño pulmonar fibrótico. El opaganib demostró una potente actividad antiviral contra el SARS-CoV-2, el virus que causa la COVID-19, mediante la inhibición total de la replicación viral en un modelo in vitro de tejido broncopulmonar humano. El opaganib también demostró una reducción en la longitud del coágulo sanguíneo, el peso y la puntuación total del trombo en un modelo preclínico de síndrome de dificultad respiratoria adquirida. Adicionalmente, estudios preclínicos in vivo[2] han demostrado que el opaganib disminuye la tasa de letalidad por infección viral de influenza y mejora del daño pulmonar inducido por Pseudomonas aeruginosa mediante la reducción de los niveles de IL-6 y TNF-alfa en los fluidos de irrigación broncoalveolares.

El opaganib fue desarrollado originalmente por Apogee Biotechnology Corp. en los Estados Unidos y terminó múltiples estudios preclínicos con éxito en modelos oncológicos, inflamatorios, gastrointestinales y radioprotectores, así como un estudio clínico de fase 1 en pacientes de cáncer con tumores sólidos avanzados y un estudio de fase 1 adicional en pacientes con mieloma múltiple.

El desarrollo del opaganib ha recibido apoyo de subvenciones y contratos de agencias gubernamentales estatales y federales de los Estados Unidos, otorgadas a Apogee Biotechnology Corp., que incluyen la NCI, BARDA, el Departamento de Defensa de los Estados Unidos y la oficina de Desarrollo de Productos Huérfanos de la FDA.

Los estudios en curso con opaganib están registrados en la página www.ClinicalTrials.gov, un servicio web del Instituto Nacional de Salud de los Estados Unidos, que otorga acceso público a la información sobre estudios clínicos con financiación pública y privada.   

Acerca de RedHill Biopharma    

RedHill Biopharma Ltd. (Nasdaq: RDHL) es una compañía especializada en biofarmacéutica centrada principalmente en enfermedades gastrointestinales e infecciosas. RedHill promueve los medicamentos gastrointestinales, Movantik® para el estreñimiento inducido por opioides en adultos[3], Talicia® para el tratamiento de infección por  Helicobacter pylori (H. pylori) en adultos[4] y Aemcolo® para el tratamiento de diarrea del viajero en adultos[5]. Los programas clave de investigación clínica en desarrollo en última etapa de RedHill incluyen los siguientes: (i) RHB-204, con un estudio de fase 3 en curso para enfermedad pulmonar por micobacterias no tuberculosas (NTM); (ii) opaganib (Yeliva®, ABC294640), un inhibidor selectivo SK2 primero en su categoría que apunta a múltiples indicaciones con un programa de fase 2/3 para la COVID-19 y estudios de fase 2 para cáncer de próstata y colangiocarcinoma en curso; (iii) RHB-107 (upamostat), un inhibidor de la serina proteasa con un estudio de pase 2/3 planeado para COVID-19 sintomático y dirigido también a múltiples enfermedades gastrointestinales inflamatorias y cáncer (iv) RHB-104, con resultados positivos de un primer estudio de fase 3 para la enfermedad de Crohn; (v) RHB-102 (Bekinda®), con resultados positivos de un estudio de fase 3 para gastroenteritis aguda y gastritis, y resultados positivos de un estudio de fase 2 para IBS-D; y (vi) RHB–106, una preparación encapsulada para el intestino. En www.redhillbio.com hay disponible más información acerca de la compañía / https://twitter.com/RedHillBio.

NOTA: Este comunicado de prensa, presentado con fines prácticos, es una versión traducida del comunicado de prensa oficial publicado por la compañía en inglés. Para leer el comunicado de prensa completo en inglés, incluido el descargo de responsabilidades de las declaraciones prospectivas, por favor, visite: https://ir.redhillbio.com/press-releases

 

Contacto de la compañía: 

Adi Frish

Director ejecutivo de Corporate & Business Development

RedHill Biopharma

+972-54-6543-112

adi@redhillbio.com 

 

Contacto de prensa (EE.UU.): 

Bryan Gibbs

Vicepresidente

Finn Partners

+1 212 529 2236

bryan.gibbs@finnpartners.com 

[1] Opaganib es un nuevo fármaco en investigación, no disponible para distribución comercial.

[2] Xia C. et al. La inhibición transitoria de esfingosina quinasa otorga protección contra el virus de la influenza A en ratones infectados. Antiviral Res. 2018 Oct; 158:171-177. Ebenezer DL et al. La Pseudomonas aeruginosa estimula la generación nuclear de la esfingosina-1-fosfato y la regulación epigenética del daño inflamatorio al pulmón. Thorax. 2019 Jun;74(6):579-591.

[3] La información completa de prescripción de Movantik® (naloxegol) se encuentra disponible en: www.Movantik.com. 

[4] La información completa de prescripción de Talicia® (omeprazol magnesio, amoxicilina y rifabutina) se encuentra disponible en: www.Talicia.com.  

[5] La información completa de prescripción de Aemcolo® (rifamicina) se encuentra disponible en: www.Aemcolo.com.

Logotipo: https://mma.prnewswire.com/media/1334141/RedHill_Biopharma_Logo.jpg 

 

FUENTE RedHill Biopharma Ltd.

RedHill Biopharma anuncia valoración positiva de la futilidad del DSMB para el estudio de fase 2/3 de opaganib para la COVID-19

TEL AVIV, Israel y RALEIGH, Carolina del Norte, 2 de febrero de 2021 /PRNewswire/ — RedHill Biopharma Ltd. (Nasdaq: RDHL) («RedHill» o la «Compañía»), una compañía especializada en la biofarmacéutica, anunció hoy que el Comité de Monitoreo de Datos y Seguridad (DSMB) independiente designado para el estudio global en fase 2/3 de opaganib[1] en pacientes con COVID-19…

TEL AVIV, Israel y RALEIGH, Carolina del Norte, 2 de febrero de 2021 /PRNewswire/ — RedHill Biopharma Ltd. (Nasdaq: RDHL) («RedHill» o la «Compañía»), una compañía especializada en la biofarmacéutica, anunció hoy que el Comité de Monitoreo de Datos y Seguridad (DSMB) independiente designado para el estudio global en fase 2/3 de opaganib[1] en pacientes con COVID-19 grave recomendó de manera unánime la continuidad del estudio, después de una valoración preprogramada de futilidad de los datos no cegados para los primeros 135 pacientes tratados en el estudio, así como de la información de seguridad de los primeros 175 pacientes. 

 

RedHill Biopharma Logo

 

«Opaganib es un nuevo inhibidor de la esfingosina quinasa-2 (SK2) administrado por vía oral con una actividad antiviral, antiinflamatoria y antitrombótica demostrada. La recomendación positiva y unánime del DSMB es un hito importante en el progreso de nuestro programa de desarrollo para la enfermedad de COVID-19. Junto con los resultados positivos del estudio de fase 2, esta recomendación unánime del DSMB para continuar el estudio global de fase 2/3 sugiere que vamos en la dirección correcta desde una perspectiva de seguridad y eficacia», comentó Mark L. Levitt, M.D., Ph.D., director médico de RedHill. «Este es un momento particularmente difícil en la lucha contra la pandemia, con mutaciones virales que aumentan las tasas de infección e impactan muchos aspectos de la respuesta de la sociedad a la pandemia. La necesidad de terapias eficaces es clara. El mecanismo de acción de Opaganib de dirige al componente SK2 de la célula humana huésped, que está involucrado tanto en la replicación viral dentro de la célula como en las respuestas inflamatorias/inmunes posteriores. Esto significa que se espera que el opaganib mantenga su actividad independientemente de las preocupantes mutaciones en la proteína spike SARS-CoV-2. Estas mutaciones subrayan el potencial del SARS-CoV-2 para desarrollar resistencia a los mAbs antivirales directos y para afectar potencialmente la efectividad de la vacuna. Esta es una ventaja importante del opaganib ante la creciente multitud de cepas virales, y promete ser una opción de tratamiento muy necesaria que puede ayudar a que los pacientes sean desconectados del oxígeno suplementario y salgan pronto del hospital».

Esta valoración de futilidad positiva por parte del DSMB, que sugiere que el estudio global de fase 2/3 avanza como se esperaba, se suma a los datos positivos de seguridad y eficacia de primera línea del estudio de fase 2 en los Estados Unidos, en el que el opaganib demostró mejoría en la reducción del requerimiento de oxígeno al final del tratamiento, el día 14, en los resultados clave de eficacia primaria y secundaria, lo que se correlaciona con la mejoría clínica según la escala ordinal de la Organización Mundial de la Salud (OMS). Los datos de la fase 2 tampoco mostraron diferencias sustanciales de seguridad entre los brazos de tratamiento tratados con opaganib y placebo, lo que se suma a la creciente base de datos de seguridad para el opaganib. En las próximas semanas se espera un análisis completo de los datos de la fase 2, incluidos los análisis de biomarcadores virales e inflamatorios, los factores de riesgo basales y la estratificación del estándar de cuidado para el tratamiento de base, los cuales se compartirán con pares para su valoración.

En línea con la rápida evolución de la práctica clínica y las directrices para el tratamiento de pacientes hospitalizados con COVID-19, cuyo objetivo es minimizar la intubación y la ventilación mecánica de los pacientes, la variable principal del estudio global de fase 2/3 ahora es la proporción de pacientes que al día 14 logran respirar por sí solos (ya no requieren oxígeno suplementario), lo que anteriormente era una una variable clave secundaria. La intubación y la ventilación mecánica siguen siendo una variable secundaria. En consecuencia, se planea un ajuste ciego del estudio para aproximadamente 460 pacientes. En la actualidad se cuenta con aproximadamente 30 sedes para el estudio en 7 países, y durante los próximos días y semanas se agregarán más sedes y países. Para el segundo trimestre de 2021 se espera contar con datos de primera línea y aplicaciones para autorización de uso potencial en emergencias a nivel global.

Acerca de Opaganib (Yeliva®, ABC294640) 

El opaganib, una nueva entidad química patentada y primera en su categoría, es un novedoso inhibidor selectivo de la esfingosina quinasa-2 (SK2) que se administra por vía oral, con actividad dual antiviral e inflamatoria demostrada que apunta al componente celular en el huésped que se encarga de la replicación del virus, y puede reducir la probabilidad de desarrollar resistencia del virus. El opaganib también ha mostrado actividad anticancerígena y tiene el potencial de apuntar a múltiples indicaciones oncológicas, virales, inflamatorias y gastrointestinales.

El opaganib recibió la designación de medicamento huérfano de la Administración de Alimentos y Medicamentos (FDA) de los Estados Unidos para el tratamiento del colangiocarcinoma y se está evaluando en un estudio de fase 2a para pacientes con colangiocarcinoma avanzado y en un estudio de fase 2 para pacientes con cáncer de próstata. El opaganib también está siendo evaluado como tratamiento para la neumonía por COVID-19 en un estudio global de fase 2/3 y ha evidenciado señales positivas de seguridad y eficacia en los datos preliminares de primera línea de un estudio de fase 2 en los Estados Unidos.

Los datos preclínicos han demostrado las actividades antiinflamatorias, antivirales y antitrombóticas del opaganib, con el potencial de aliviar trastornos inflamatorios del pulmón, como la neumonía, y de mitigar el daño pulmonar fibrótico. El opaganib demostró una potente actividad antiviral contra el SARS-CoV-2, el virus que causa la COVID-19, mediante la inhibición total de la replicación viral en un modelo in vitro de tejido broncopulmonar humano. El opaganib también demostró una reducción en la longitud del coágulo sanguíneo, el peso y la puntuación total del trombo en un modelo preclínico de síndrome de dificultad respiratoria adquirida. Adicionalmente, estudios preclínicos in vivo[2] han demostrado que el opaganib disminuye la tasa de letalidad por infección viral de influenza y mejora del daño pulmonar inducido por Pseudomonas aeruginosa mediante la reducción de los niveles de IL-6 y TNF-alfa en los fluidos de irrigación broncoalveolares.

El opaganib fue desarrollado originalmente por Apogee Biotechnology Corp. en los Estados Unidos y terminó múltiples estudios preclínicos con éxito en modelos oncológicos, inflamatorios, gastrointestinales y radioprotectores, así como un estudio clínico de fase 1 en pacientes de cáncer con tumores sólidos avanzados y un estudio de fase 1 adicional en pacientes con mieloma múltiple.

El desarrollo del opaganib ha recibido apoyo de subvenciones y contratos de agencias gubernamentales estatales y federales de los Estados Unidos, otorgadas a Apogee Biotechnology Corp., que incluyen la NCI, BARDA, el Departamento de Defensa de los Estados Unidos y la oficina de Desarrollo de Productos Huérfanos de la FDA.

Los estudios en curso con opaganib están registrados en la página www.ClinicalTrials.gov, un servicio web del Instituto Nacional de Salud de los Estados Unidos, que otorga acceso público a la información sobre estudios clínicos con financiación pública y privada.   

Acerca de RedHill Biopharma    

RedHill Biopharma Ltd. (Nasdaq: RDHL) es una compañía especializada en biofarmacéutica centrada principalmente en enfermedades gastrointestinales e infecciosas. RedHill promueve los medicamentos gastrointestinales, Movantik® para el estreñimiento inducido por opioides en adultos[3], Talicia® para el tratamiento de infección por  Helicobacter pylori (H. pylori) en adultos[4] y Aemcolo® para el tratamiento de diarrea del viajero en adultos[5]. Los programas clave de investigación clínica en desarrollo en última etapa de RedHill incluyen los siguientes: (i) RHB-204, con un estudio de fase 3 en curso para enfermedad pulmonar por micobacterias no tuberculosas (NTM); (ii) opaganib (Yeliva®, ABC294640), un inhibidor selectivo SK2 primero en su categoría que apunta a múltiples indicaciones con un programa de fase 2/3 para la COVID-19 y estudios de fase 2 para cáncer de próstata y colangiocarcinoma en curso; (iii) RHB-107 (upamostat), un inhibidor de la serina proteasa con un estudio de pase 2/3 planeado para COVID-19 sintomático y dirigido también a múltiples enfermedades gastrointestinales inflamatorias y cáncer (iv) RHB-104, con resultados positivos de un primer estudio de fase 3 para la enfermedad de Crohn; (v) RHB-102 (Bekinda®), con resultados positivos de un estudio de fase 3 para gastroenteritis aguda y gastritis, y resultados positivos de un estudio de fase 2 para IBS-D; y (vi) RHB–106, una preparación encapsulada para el intestino. En www.redhillbio.com hay disponible más información acerca de la compañía / https://twitter.com/RedHillBio.

NOTA: Este comunicado de prensa, presentado con fines prácticos, es una versión traducida del comunicado de prensa oficial publicado por la compañía en inglés. Para leer el comunicado de prensa completo en inglés, incluido el descargo de responsabilidades de las declaraciones prospectivas, por favor, visite: https://ir.redhillbio.com/press-releases

 

Contacto de la compañía: 

Adi Frish

Director ejecutivo de Corporate & Business Development

RedHill Biopharma

+972-54-6543-112

adi@redhillbio.com 

 

Contacto de prensa (EE.UU.): 

Bryan Gibbs

Vicepresidente

Finn Partners

+1 212 529 2236

bryan.gibbs@finnpartners.com 

[1] Opaganib es un nuevo fármaco en investigación, no disponible para distribución comercial.

[2] Xia C. et al. La inhibición transitoria de esfingosina quinasa otorga protección contra el virus de la influenza A en ratones infectados. Antiviral Res. 2018 Oct; 158:171-177. Ebenezer DL et al. La Pseudomonas aeruginosa estimula la generación nuclear de la esfingosina-1-fosfato y la regulación epigenética del daño inflamatorio al pulmón. Thorax. 2019 Jun;74(6):579-591.

[3] La información completa de prescripción de Movantik® (naloxegol) se encuentra disponible en: www.Movantik.com. 

[4] La información completa de prescripción de Talicia® (omeprazol magnesio, amoxicilina y rifabutina) se encuentra disponible en: www.Talicia.com.  

[5] La información completa de prescripción de Aemcolo® (rifamicina) se encuentra disponible en: www.Aemcolo.com.

Logotipo: https://mma.prnewswire.com/media/1334141/RedHill_Biopharma_Logo.jpg 

 

FUENTE RedHill Biopharma Ltd.

Twin Peaks Lodging Growing and Set to Thrive Through the Pandemic with Maestro PMS

MARKHAM, Ontario, Feb. 2, 2021 /PRNewswire-PRWeb/ — Thankfully, the lingering pandemic of 2020 has not devastated every hotel in every market. Twin Peaks Lodge and Hot Springs, located in the tourist town of Ouray, Colorado, is weathering the health and economic crisis…

MARKHAM, Ontario, Feb. 2, 2021 /PRNewswire-PRWeb/ — Thankfully, the lingering pandemic of 2020 has not devastated every hotel in every market. Twin Peaks Lodge and Hot Springs, located in the tourist town of Ouray, Colorado, is weathering the health and economic crisis quite well due in part to its vast array of outdoor activities and its migration to Maestro PMS. Nearly doubling its accommodations footprint in 2018 and adding a spa required the independent lodge to find a new property-management system provider. Maestro PMS, with its sophisticated feature set and array of mobile and touchless technologies designed to reduce or eliminate the need for physical contact between guests and staff, proved to be the best choice.

«What a smart decision we made choosing Maestro,» said Twin Peaks Lodge and Hot Springs Assistant General Manager Beth Bridges. «We were growing and needed a super flexible property-management system that could grow right along with us; we anticipate reaching 250 rooms by 2024. We began looking for a single system that could run all front and back office operations, Sage Spa, and work with Mineshaft Restaurant’s Silverware POS. Maestro had everything we needed — the PMS with integrated ResWave online booking engine, yield management, enhanced GDS/OTA integration, central reservations, mobile housekeeping, a Spa and Activities module, and workorder management. What we did not foresee was just how well prepared we were to meet guests’ needs amidst a global health crisis.

«Maestro’s Self Check-In Kiosk partner integration is enabling us to register guests safely and meet social distancing requirements,» she said. «When guests arrive, they approach a kiosk rather than a front desk agent, enter their contact details, vehicle information, and electronically sign the digital registration card. All information is automatically saved in Maestro. The kiosk then prints out directions to the guest’s room, along with a map of the property, and dispenses their room key. It’s completely contactless, and guests and staff appreciate the simplicity. Of course, should a guest need personal assistance, our front desk team is standing by to help. This is just one of the many ways that Maestro is supporting us today.»

In addition to kiosk-only check in, Twin Peaks Lodge and Hot Springs is limiting its lobby, Sage Spa, and pool access; stopping daily housekeeping (guests staying more than one night can request additional linens or toiletries by contacting the front desk and they can place trash outside their doors in provided bags); and sending digital receipts (no paper) to guests’ email addresses on file. The Mineshaft Restaurant is open for outdoor dining only from Memorial Day through Labor Day. The rest of the year, foodservice is available via online ordering with room delivery or pick up, and a continental style grab-and-go breakfast is available at the front desk for pick up, all managed through the unique integration between Maestro PMS and Silverware POS.

«Due to COVID restrictions, we’ve had to close the room that we typically used for breakfast,» Bridges said. «That service disruption turned into an opportunity, as we are now using Maestro’s Sales and Catering functionality to book that space for meetings. The 150-seat room is large enough to comfortably accommodate people 10-feet apart. Local companies have used it multiple times for training, and soon we have a teachers’ conference coming in. This is just another example of how Maestro is growing with us; their sales-and-catering module enabled us to create revenue opportunities. Now our new meeting business is centralized within Maestro.»

Bridges said today her team is only using a third of the functionality that Maestro PMS offers. Being able to successfully operate and manage her hotel and meet the contactless needs of today’s guests with limited use «speaks volumes about just how awesome Maestro really is.» In the future, Bridges said she hopes to leverage Maestro’s Condo Management module, as some of the units have private owners. Regarding Maestro’s service and support, Bridges calls it «super responsive.»

«We are delighted that Twin Peaks Lodge and Hot Springs is such a satisfied Maestro client,» said Warren Dehan, Maestro president. «No one saw COVID coming, but like Twin Peaks, our clients tell us we have equipped them with the tools they need to not just survive but thrive as business returns and guests visit with new expectations in response to COVID. Maestro is here for our clients, large and small. No matter how good our PMS and contactless options may be, it must be backed by exceptional service. That’s something that we take great pride in maintaining for all our clients. We look forward to watching Twin Peaks grow in the coming years and add more Maestro Modules and tools as needed.»

About Maestro
Maestro is the preferred cloud and on-premises PMS solution for independent hotels, luxury resorts, conference centers, vacation rentals, and multi-property groups. Maestro’s PCI certified and EMV ready enterprise system offers 20+ integrated modules on a single database including web and mobile apps to increase profitability, drive direct bookings, centralize operations, and enable operators to engage guests with a personalized experience. For over 40 years Maestro’s Diamond Plus Service has provided unparalleled 24/7 North American based support and education services to keep hospitality groups operational and productive. Click here for more information on Maestro. Click here to get your free PMS Buying guide.

About Twin Peaks Lodge and Hot Springs
Located in Ouray, Colorado, the Twin Peaks Lodge and Hot Springs is a full-service hotel offering Ouray lodging accommodations near the mountains. The hotel is within walking distance to shops and restaurants and there are hundreds of miles of biking, Jeep, and hiking trails to explore. It is located at 125 3rd Avenue, Ouray, Colorado 81427. For more information on the hotel, Ouray lodging, or Twin Peaks lodging room types, please call 800-207-2700.

Media Contact

Barbara Worcester, Maestro PMS, 440-930-5770, barbw@prproconsulting.com

 

SOURCE Maestro PMS

The Home Depot Bringing 1,500 New Jobs to Dallas-Fort Worth Metro with New Distribution Center

DALLAS, Feb. 2, 2021 /PRNewswire-HISPANIC PR WIRE/ — The Home Depot® today announced it has opened a new distribution center in Dallas to fulfill online orders and store orders. The 1.5 million square-foot distribution center is designed to meet customers’ delivery needs through multiple channels, whether delivering items directly to customers’ homes or for pickup at local stores.

<img…

DALLAS, Feb. 2, 2021 /PRNewswire-HISPANIC PR WIRE/ — The Home Depot® today announced it has opened a new distribution center in Dallas to fulfill online orders and store orders. The 1.5 million square-foot distribution center is designed to meet customers’ delivery needs through multiple channels, whether delivering items directly to customers’ homes or for pickup at local stores.

The Home Depot logo.

The company’s newest Dallas supply chain site also manages customer delivery and installation of large appliances such as washers, dryers, and refrigerators ordered in stores or online. From final sale to removal of old appliances, the operation offers an improved purchase and delivery experience for Home Depot customers in the Dallas-Fort Worth area.

«We’re focused on creating an easier and more convenient shopping experience for our customers’ home improvement needs, whether they shop in stores or online,» said Stephanie Smith, senior vice president of supply chain for The Home Depot. «Our supply chain is the foundation for delivering on our Pro and DIY customers’ changing expectations, which is why we’re investing to offer same day and next day delivery to 90 percent of the U.S. population.» 

The Dallas-Fort Worth market is a key hub for The Home Depot’s delivery and supply chain strategy. Early last year, the company opened another delivery center at the new Dallas campus that delivers building materials and other bulky products directly to DIY and Pro customers when and where they need it, all within the same day or the next day of ordering.

The new facility features a zero-emission hydrogen fuel cell charging station — a sustainable and more efficient way to power material handling equipment. It also includes more than six miles of mechanized lines and other automation technologies that enable increased product flow.

The facility is part of the company’s $1.2 billion investment to expand its national distribution and delivery network. Ultimately, the company’s supply chain footprint in the Dallas-Fort Worth area will grow from 2.1 million square feet to 4.5 million square feet and will create approximately 1,500 new jobs by the end of this year. The company currently operates 20 distribution centers in the state.

Interested jobseekers should visit careers.homedepot.com or text JOBS to 52270 for a link to apply for local positions.

ABOUT THE HOME DEPOT
The Home Depot is the world’s largest home improvement specialty retailer, with 2,296 retail stores in all 50 states, the District of Columbia, Puerto Rico, U.S. Virgin Islands, Guam, 10 Canadian provinces and Mexico. In fiscal 2019, The Home Depot had sales of $110.2 billion and earnings of $11.2 billion. The company employs more than 400,000 associates. The Home Depot’s stock is traded on the New York Stock Exchange (NYSE: HD) and is included in the Dow Jones industrial average and Standard & Poor’s 500 index.

Logo – https://mma.prnewswire.com/media/118058/the_home_depot_logo.jpg

SOURCE The Home Depot

UL Grants ERG First Wind Turbine Lifetime Extension Certificate

NORTHBROOK, Ill., Feb. 2, 2021 /PRNewswire/ — UL, the leading global safety science leader, announced today that ERG, producers of electricity from clean, renewable and sustainable sources, is the first entity to receive a certificate for UL 4143, the Standard for Wind Turbine Generator Life Time Extension, for an ERG wind farm in Italy.

<a…

NORTHBROOK, Ill., Feb. 2, 2021 /PRNewswire/ — UL, the leading global safety science leader, announced today that ERG, producers of electricity from clean, renewable and sustainable sources, is the first entity to receive a certificate for UL 4143, the Standard for Wind Turbine Generator Life Time Extension, for an ERG wind farm in Italy.

UL 4143 is a process of assessing lifetime extension for a wind farm through onsite inspection of turbines and blades focused on structural integrity, and an analytical evaluation of the site conditions to determine the remaining useful life for each structural component. The evaluation is done using UL’s aerolastic models with inputs from the plant such as building permits, maintenance and inspection records, SCADA data, power curtailment, type certificates, and more. The outcome is summarized in a final report defining the remaining useful life (RUL) of the plant and the conditions under which it can be achieved. 

ERG, one of the largest onshore wind energy operators in Europe with a total installed capacity of 1.9 GW, owns a fleet of wind turbines in Italy, France and Germany that are reaching 20 years of operation, the typical design life of a wind turbine. To achieve the UL 4143 Standard certificate, UL performed a number of lifetime assessment and aging plant analyses. ERG’s wind turbines were analyzed to determine the RUL of the operational wind turbines. The structural integrity of the turbines was also confirmed by means of load simulations performed to assess the safety and viability of extending turbine life. Additionally, a risk analysis evaluation and on-site inspection was performed to evaluate potential rising risks connected with the aging turbines.

«Turbines are designed for specific International Electrotechnical Commission wind class conditions based on average wind speed, extreme gusts, and turbulence, and typically for a 20-year expected lifespan. In many cases the actual wind conditions are less aggressive than design conditions, and enough margin exists in the design that the turbine can safely operate well beyond its intended life,» said Michael Brower, vice president in the Renewables division at UL. «The goals for UL are to support the sustainable, safe operation and to help maximize the life and value of their operating wind assets.»

UL holds a leading position in the independent lifetime extension evaluation market having recently surpassed 20 GW assessed around the world for over 9000 turbines, 160 wind turbine models from 27 manufacturers.  

To read more about UL’s Lifetime Extension services, visit ul.com/renewables.   

About UL
UL helps create a better world by applying science to solve safety, security and sustainability challenges. We empower trust by enabling the safe adoption of innovative new products and technologies. Everyone at UL shares a passion to make the world a safer place. All of our work, from independent research and standards development, to testing and certification, to providing analytical and digital solutions, helps improve global well-being. Businesses, industries, governments, regulatory authorities and the public put their trust in us so they can make smarter decisions. To learn more, visit UL.com. To learn more about our nonprofit activities, visit UL.org.

Press Contact:
ULNews@ul.com
1+847.664.8425

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/ul-grants-erg-first-wind-turbine-lifetime-extension-certificate-301219897.html

SOURCE UL

The Home Depot Bringing 1,500 New Jobs to Dallas-Fort Worth Metro with New Distribution Center

DALLAS, Feb. 2, 2021 /PRNewswire/ — The Home Depot® today announced it has opened a new distribution center in Dallas to fulfill online orders and store orders. The 1.5 million square-foot distribution center is designed to meet customers’ delivery needs through multiple channels, whether delivering items directly to customers’ homes or for pickup at local stores.

<a…

DALLAS, Feb. 2, 2021 /PRNewswire/ — The Home Depot® today announced it has opened a new distribution center in Dallas to fulfill online orders and store orders. The 1.5 million square-foot distribution center is designed to meet customers’ delivery needs through multiple channels, whether delivering items directly to customers’ homes or for pickup at local stores.

The company’s newest Dallas supply chain site also manages customer delivery and installation of large appliances such as washers, dryers, and refrigerators ordered in stores or online. From final sale to removal of old appliances, the operation offers an improved purchase and delivery experience for Home Depot customers in the Dallas-Fort Worth area.

«We’re focused on creating an easier and more convenient shopping experience for our customers’ home improvement needs, whether they shop in stores or online,» said Stephanie Smith, senior vice president of supply chain for The Home Depot. «Our supply chain is the foundation for delivering on our Pro and DIY customers’ changing expectations, which is why we’re investing to offer same day and next day delivery to 90 percent of the U.S. population.» 

The Dallas-Fort Worth market is a key hub for The Home Depot’s delivery and supply chain strategy. Early last year, the company opened another delivery center at the new Dallas campus that delivers building materials and other bulky products directly to DIY and Pro customers when and where they need it, all within the same day or the next day of ordering.

The new facility features a zero-emission hydrogen fuel cell charging station — a sustainable and more efficient way to power material handling equipment. It also includes more than six miles of mechanized lines and other automation technologies that enable increased product flow.

The facility is part of the company’s $1.2 billion investment to expand its national distribution and delivery network. Ultimately, the company’s supply chain footprint in the Dallas-Fort Worth area will grow from 2.1 million square feet to 4.5 million square feet and will create approximately 1,500 new jobs by the end of this year. The company currently operates 20 distribution centers in the state.

Interested jobseekers should visit careers.homedepot.com or text JOBS to 52270 for a link to apply for local positions.

ABOUT THE HOME DEPOT
The Home Depot is the world’s largest home improvement specialty retailer, with 2,296 retail stores in all 50 states, the District of Columbia, Puerto Rico, U.S. Virgin Islands, Guam, 10 Canadian provinces and Mexico. In fiscal 2019, The Home Depot had sales of $110.2 billion and earnings of $11.2 billion. The company employs more than 400,000 associates. The Home Depot’s stock is traded on the New York Stock Exchange (NYSE: HD) and is included in the Dow Jones industrial average and Standard & Poor’s 500 index.                                                                                                                         

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/the-home-depot-bringing-1-500-new-jobs-to-dallas-fort-worth-metro-with-new-distribution-center-301220122.html

SOURCE The Home Depot

Southern Company gets high marks for environmental transparency

ATLANTA, Feb. 2, 2021 /PRNewswire/ — Southern Company earned a score of A- from the CDP Climate Change Disclosure for its environmental transparency and leadership within the North America region and thermal power generation sector. In 2019, the company received a B.

<a href="https://mma.prnewswire.com/media/808925/Southern_Company_Logo.html"…

ATLANTA, Feb. 2, 2021 /PRNewswire/ — Southern Company earned a score of A- from the CDP Climate Change Disclosure for its environmental transparency and leadership within the North America region and thermal power generation sector. In 2019, the company received a B.

The CDP, formally the Carbon Disclosure Project, is a global nonprofit that releases annual scores to incentivize and guide companies and municipalities in becoming leaders in environmental transparency and action.

By completing CDP’s annual request for climate change disclosure, Southern Company is demonstrating the transparency and accountability vital to tracking progress toward a thriving, sustainable future.

«Southern Company is committed to increasing disclosure of our system’s strategy and process for planning to a net zero future. Participating in the CDP climate disclosure is another step in that process,» said Jeff Burleson, Southern Company senior vice president environmental and system planning. «Our commitment to delivering energy and energy solutions includes conserving and protecting the environment for today and for future generations.»

In 2020, Southern Company moved to a long-term greenhouse gas emissions reduction goal of net zero emissions by 2050.  This replaces the low- to no-carbon goal the company announced in 2018. The Southern Company system has already made significant progress toward our 2030 goal of reducing emissions by 50% from 2007 levels. 

Building on its disclosure to CDP, Southern Company also issued the Implementation and Action toward Net Zero report in 2020.

More than 9,600 companies disclosed environmental data through CDP in 2020. This is in addition to the more than 920 cities, states and regions that disclosed in 2019, making CDP’s platform one of the richest sources of information globally on how companies and governments are leading on environmental performance.

«Corporations have a significant role to play in solving the environmental crisis, and the first essential step is to be transparent around their current environmental impacts,» said Ateli Iyalla, managing director at CDP North America. «Southern Company is among a critical mass of companies that are disclosing their environmental impact to CDP annually – thereby uncovering risks and opportunities, boosting their competitive advantage and tracking press toward sound environmental management. I look forward to seeing them advance their action and continue on a path toward true environmental stewardship.»

About Southern Company
Southern Company (NYSE: SO) is a leading energy company serving 9 million customers through its subsidiaries. The company provides clean, safe, reliable and affordable energy through electric operating companies in three states, natural gas distribution companies in four states, a competitive generation company serving wholesale customers across America, a leading distributed energy infrastructure company, a fiber optics network and telecommunications services. Southern Company brands are known for excellent customer service, high reliability and affordable prices below the national average. For more than a century, we have been building the future of energy and developing the full portfolio of energy resources, including carbon-free nuclear, advanced carbon capture technologies, natural gas, renewables, energy efficiency and storage technology. Through an industry-leading commitment to innovation and a low-carbon future, Southern Company and its subsidiaries develop the customized energy solutions our customers and communities require to drive growth and prosperity. Our uncompromising values ensure we put the needs of those we serve at the center of everything we do and govern our business to the benefit of our world. Our corporate culture and hiring practices have been recognized nationally by the U.S. Department of Defense, G.I. Jobs magazine, DiversityInc, Black Enterprise, Forbes and the Women’s Choice Award. To learn more, visit www.southerncompany.com.

About CDP  
CDP is a global non-profit that drives companies and governments to reduce their greenhouse gas emissions, safeguard water resources and protect forests. Voted number one climate research provider by investors and working with institutional investors with assets of US$106 trillion, we leverage investor and buyer power to motivate companies to disclose and manage their environmental impacts. Over 9,600 companies with over 50% of global market capitalization disclosed environmental data through CDP in 2020. This is in addition to the over 920 cities, states and regions who disclosed in 2019, making CDP’s platform one of the richest sources of information globally on how companies and governments are driving environmental change. CDP is a founding member of the We Mean Business Coalition. Visit https://cdp.net/en or follow us @CDP to find out more.   

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/southern-company-gets-high-marks-for-environmental-transparency-301220097.html

SOURCE Southern Company

Thermo Fisher Scientific Introduces New Handheld XRF Analyzer for Elemental Detection

TEWKSBURY, Mass., Feb. 2, 2021 /PRNewswire/ — Material verification and contaminant detection are crucial steps in quality assurance. From analyzing oil and gas pipelines, to testing polluted soil, if verification isn’t accurately and correctly performed, it can pose a potential threat to public safety. As a result, inspection personnel require a versatile elemental analyzer that provides peak-performance and real-time insights to complete the task at hand and defend against potentially dangerous…

TEWKSBURY, Mass., Feb. 2, 2021 /PRNewswire/ — Material verification and contaminant detection are crucial steps in quality assurance. From analyzing oil and gas pipelines, to testing polluted soil, if verification isn’t accurately and correctly performed, it can pose a potential threat to public safety. As a result, inspection personnel require a versatile elemental analyzer that provides peak-performance and real-time insights to complete the task at hand and defend against potentially dangerous scenarios.

The new Thermo Scientific Niton XL5 Plus handheld XRF analyzer helps businesses mitigate risk through the use of x-ray fluorescence technology by providing lab quality elemental analysis directly in the field. The Niton XL5 Plus is the smallest and lightest portable XRF analyzer on the market and weighs only 2.8lbs. It provides users with greater accessibility in hard to maneuver workspaces while reducing operator fatigue. Featuring enhanced software and improved detector technology, the Niton XL5 Plus provides unprecedented analytical performance and accuracy when analyzing both light elements and heavy metals. The versatility of the Niton XL5 Plus makes it an ideal tool for numerous applications where elemental analysis is needed.

«Inspection personnel tasked with material verification or contaminant detection are faced with constant pressure to provide quick and accurate analysis. A challenging task when considering the often harsh or remote environments that these professionals work in,» said Chloe Hansen-Toone, vice president and general manager with Thermo Fisher’s field and safety instruments business. «With the Niton XL5 Plus, we’ve made significant advancements to our legacy handheld XRF analyzer that improves the accuracy and accessibility of data, empowering operators to make insightful decisions that enable a safer worksite.»

As a go-to resource for organizations in a variety of industrial settings, the Niton XL5 Plus features new detector protection to mitigate the risk of damage to the detector window. This greatly enhances the durability of the XRF analyzer, particularly in recycling and scrap metal settings where punctures from sharp objects is common. As a result, operators can avoid costly repairs and enjoy an extended product lifetime.

For more information on the Thermo Scientific Niton™ XL5 Plus handheld XRF analyzer, please visit www.thermofisher.com/NitonXL5Plus

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 80,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com.

 

Media Contact Information:
Nick Brown
Inkhouse for Thermo Fisher Scientific
401-595-7836
thermofisher@inkhouse.com

Secondary Contact Information:
Meredith Wilshere
Inkhouse for Thermo Fisher Scientific
516-318-2951

 

 

Cision View original content:http://www.prnewswire.com/news-releases/thermo-fisher-scientific-introduces-new-handheld-xrf-analyzer-for-elemental-detection-301219849.html

SOURCE Thermo Fisher Scientific